Miso Kim

12PUBLICATIONS
110CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersPharmaceutical delivery technologiesCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 31, 2026
Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01.

|Aug 05, 2026
Early and High-Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation.

|Aug 16, 2024
Transcriptomic Heterogeneity of EGFR-Mutant Non-Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer.

Songji Oh, Jaemoon Koh, Tae Min Kim

|Jan 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

Robert J Motzer, Camillo Porta, Masatoshi Eto

|Oct 25, 2023
Prognostic utility of body composition parameters based on computed tomography analysis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

Ji Eun Park, Jaemin Jo, Jeonghwan Youk

|Oct 20, 2023
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.

William K Kelly, Daniel C Danila, Chia-Chi Lin

Pageof 2

Frequent Collaborators

6 joint publications

Bhumsuk Keam

3 joint publications

Tae Min Kim

3 joint publications

Dong-Wan Kim

2 joint publications

Youngjoo Lee